Department of Orthopaedic Surgery, Hospital Sant Joan Despí Moisès Broggi, C/ Jacint Verdaguer, 08970, Sant Joan Despí, Barcelona, Spain.
Department of Oncological Orthopaedic Surgery, Hospital de La Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Clin Transl Oncol. 2019 Oct;21(10):1374-1382. doi: 10.1007/s12094-019-02067-1. Epub 2019 Feb 23.
Survival in Ewing's sarcoma (ES) has increased with the use of chemotherapy. Surgical techniques such as limb salvage (LS) have been developed. Survival and adverse events have been widely studied in general series of ES, but there are few specific series of ES cases treated by LS, despite this being the most commonly used (surgical) approach. The aim of this study was to determine survival and prognostic factors in ES patients undergoing LS.
We analysed all ES patients treated between January 1984 and May 2008 and selected all those treated by systemic multimodal therapy and LS. We assessed the influence of patient characteristics, tumour parameters and therapeutic results in event-free survival (EFS).
Ninety patients were included. Fifty of them were treated by systemic multimodal therapy and locally by LS. ean age was 20 years. Overall survival (OS) was 68.8% and EFS was 60.6% at years. In the univariate analysis, pelvic location, age and response to chemotherapy were associated with poor prognosis. After multivariate analysis, poor response to treatment, pelvis location and age between 12 and 17 years were found to be independent prognostic factors. Dissemination at diagnosis was not a prognostic factor.
OS and EFS in ES treated by LS were similar to findings in previous ES studies. factors are no different, except for the presence of metastasis at diagnosis.
随着化疗的应用,尤因氏肉瘤(ES)的生存率有所提高。已经开发出了诸如保肢(LS)等外科技术。ES 的一般系列中广泛研究了生存率和不良事件,但很少有专门针对 LS 治疗的 ES 病例的具体系列,尽管这是最常用的(手术)方法。本研究旨在确定接受 LS 治疗的 ES 患者的生存率和预后因素。
我们分析了 1984 年 1 月至 2008 年 5 月期间接受治疗的所有 ES 患者,并选择了所有接受全身多模式治疗和 LS 治疗的患者。我们评估了患者特征、肿瘤参数和治疗结果对无事件生存(EFS)的影响。
共纳入 90 例患者。其中 50 例接受全身多模式治疗和局部 LS 治疗。平均年龄为 20 岁。总体生存率(OS)为 68.8%,EFS 为 60.6%。在单因素分析中,骨盆位置、年龄和对化疗的反应与预后不良相关。多因素分析后发现,治疗反应不良、骨盆位置和 12-17 岁的年龄是独立的预后因素。诊断时的转移不是预后因素。
LS 治疗的 ES 的 OS 和 EFS 与先前的 ES 研究结果相似。除了诊断时存在转移外,预后因素没有不同。